Crossbow Therapeutics is a biotechnology company focused on developing novel T-cell receptor (TCR)-mimetic antibody therapies for the treatment of cancer. Their approach aims to leverage the specificity of T-cell receptors to target cancer cells with high precision. The company recently announced a $77 million Series B financing round to advance its pipeline.